Travere Therapeutics names Bradley Campbell CEO, effective Dec. 1, 2026

TVTX•2026-09-21

Campbell's prior experience

Campbell previously led Amicus Therapeutics as president and CEO. He also held commercial and business development roles at Genzyme and Bristol-Myers Squibb.

Travere names Bradley Campbell as CEO

Travere Therapeutics named Bradley L. Campbell as president, CEO and board member, effective Dec. 1, 2026.

Outgoing CEO Eric Dube will serve until that date, then remain executive advisor through Feb. 15, 2027.

Travere Therapeutics names Bradley Campbell CEO, effective Dec. 1, 2026

Campbell's prior experience

Travere names Bradley Campbell as CEO

Related News

Orion Group extends CEO, general counsel employment agreements through Dec. 31, 2026

NYSE halts SOS shares pending disclosure of $0.18 stock sale deal

Coeur Mining CEO Krebs presents at Mining Forum Americas

Xenia Hotels & Resorts declares USD 0.14 per-share dividend for Q3 2026

MindWalk Holdings announces annual shareholder meeting